Renatus M, Engh R A, Stubbs M T, Huber R, Fischer S, Kohnert U, Bode W
Max-Planck-Institute of Biochemistry, Department of Structural Research, Martinsried, Germany.
EMBO J. 1997 Aug 15;16(16):4797-805. doi: 10.1093/emboj/16.16.4797.
Tissue type plasminogen activator (tPA) is the physiological initiator of fibrinolysis, activating plasminogen via highly specific proteolysis; plasmin then degrades fibrin with relatively broad specificity. Unlike other chymotrypsin family serine proteinases, tPA is proteolytically active in a single-chain form. This form is also preferred for therapeutic administration of tPA in cases of acute myocardial infarction. The proteolytic cleavage which activates most other chymotrypsin family serine proteinases increases the catalytic efficiency of tPA only 5- to 10-fold. The X-ray crystal structure of the catalytic domain of recombinant human single-chain tPA shows that Lys156 forms a salt bridge with Asp194, promoting an active conformation in the single-chain form. Comparisons with the structures of other serine proteinases that also possess Lys156, such as trypsin, factor Xa and human urokinase plasminogen activator (uPA), identify a set of secondary interactions which are required for Lys156 to fulfil this activating role. These findings help explain the anomalous single-chain activity of tPA and may suggest strategies for design of new therapeutic plasminogen activators.
组织型纤溶酶原激活剂(tPA)是纤维蛋白溶解的生理启动因子,通过高度特异性的蛋白水解作用激活纤溶酶原;然后纤溶酶以相对较广的特异性降解纤维蛋白。与其他胰凝乳蛋白酶家族丝氨酸蛋白酶不同,tPA以单链形式具有蛋白水解活性。在急性心肌梗死病例中,这种形式也是tPA治疗给药的首选形式。激活大多数其他胰凝乳蛋白酶家族丝氨酸蛋白酶的蛋白水解切割仅使tPA的催化效率提高5至10倍。重组人单链tPA催化结构域的X射线晶体结构表明,赖氨酸156(Lys156)与天冬氨酸194(Asp194)形成盐桥,促进单链形式的活性构象。与同样含有Lys156的其他丝氨酸蛋白酶结构进行比较,如胰蛋白酶、凝血因子Xa和人尿激酶型纤溶酶原激活剂(uPA),确定了Lys156发挥这种激活作用所需的一组二级相互作用。这些发现有助于解释tPA异常的单链活性,并可能为新型治疗性纤溶酶原激活剂的设计提供策略。